Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Brain Hemorrhage - Pipeline Review, H2 2016, provides an overview of the Brain Hemorrhage (Central Nervous System) pipeline landscape.
Brain hemorrhage is a type of stroke. It is caused by the bursting of an artery in the brain that leads to localized bleeding in the surrounding tissues. This bleeding kills the brain cells. The common risk factors of brain haemorrhages include head trauma, high blood pressure, aneurysm, blood vessel abnormalities, amyloid angiopathy, blood or bleeding disorders such as hemophilia and sickle cell anemia, liver disease and brain tumors. Symptoms include sudden severe headache, seizures, weakness in an arm or leg, nausea or vomiting, lethargy, changes in vision, tingling or numbness, difficulty in speaking or understanding speech, difficulty in swallowing, difficulty in writing or reading, loss of fine motor skills such as hand tremors, loss of coordination, loss of balance, abnormal sense of taste and loss of consciousness.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Brain Hemorrhage - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Brain Hemorrhage (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Brain Hemorrhage (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Hemorrhage and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 5 and 1 respectively.Brain Hemorrhage.
Brain Hemorrhage (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Hemorrhage (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Brain Hemorrhage (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Brain Hemorrhage (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Brain Hemorrhage (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Brain Hemorrhage (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Brain Hemorrhage (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Brain Hemorrhage (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Bio Products Laboratory Ltd
Edge Therapeutics Inc
F. Hoffmann-La Roche Ltd
Fina Biotech
MediPost Co Ltd
Pfizer Inc
Remedy Pharmaceuticals Inc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Brain Hemorrhage Overview 6
Therapeutics Development 7
Pipeline Products for Brain Hemorrhage - Overview 7
Brain Hemorrhage - Therapeutics under Development by Companies 8
Brain Hemorrhage - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Brain Hemorrhage - Products under Development by Companies 12
Brain Hemorrhage - Companies Involved in Therapeutics Development 13
Bio Products Laboratory Ltd 13
Edge Therapeutics Inc 14
F. Hoffmann-La Roche Ltd 15
Fina Biotech 16
MediPost Co Ltd 17
Pfizer Inc 18
Remedy Pharmaceuticals Inc 19
Brain Hemorrhage - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
alteplase - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
aprotinin SR - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CN-105 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
glyburide - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
haptoglobin (human) - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
PF-05230907 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Pneumostem - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
PRC-14 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Recombinant Protein to Inhibit tPA and uPA for Intracranial Hemorrhage - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
RMP-HPE - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis and Pneumoconiosis - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Stem Cell Therapy for Brain Stroke - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Brain Hemorrhage - Dormant Projects 45
Brain Hemorrhage - Discontinued Products 46
Brain Hemorrhage - Product Development Milestones 47
Featured News & Press Releases 47
Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of EG-1964 To Treat Brain Hemorrhage 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List of Tables
Number of Products under Development for Brain Hemorrhage, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Brain Hemorrhage - Pipeline by Bio Products Laboratory Ltd, H2 2016 13
Brain Hemorrhage - Pipeline by Edge Therapeutics Inc, H2 2016 14
Brain Hemorrhage - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 15
Brain Hemorrhage - Pipeline by Fina Biotech, H2 2016 16
Brain Hemorrhage - Pipeline by MediPost Co Ltd, H2 2016 17
Brain Hemorrhage - Pipeline by Pfizer Inc, H2 2016 18
Brain Hemorrhage - Pipeline by Remedy Pharmaceuticals Inc, H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Brain Hemorrhage - Dormant Projects, H2 2016 45
Brain Hemorrhage - Discontinued Products, H2 2016 46
List of Figures
Number of Products under Development for Brain Hemorrhage, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Targets, H2 2016 21
Number of Products by Stage and Targets, H2 2016 21
Number of Products by Mechanism of Actions, H2 2016 23
Number of Products by Stage and Mechanism of Actions, H2 2016 23
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Types, H2 2016 27
